Hoba Therapeutics: EIC Accelerator Nerve-Pain Drug and the Clinical Evidence
Neuropathic pain, the burning and stabbing pain of damaged nerves, is badly served by today's drugs. The standard treatments dull the signal, often with heavy side effects, and opioids bring their own risks. Hoba Therapeutics, a Copenhagen company founded in 2016 by Novo Holdings and Borean Innovation, according to Novo Holdings, is developing something different: a natural human protein that, the company says, repaired nerves in animal models rather than masking the pain.
In 2021 the European Innovation Council granted €2,325,312.50 to take that protein, HB-086, and a sister molecule for hearing loss into clinical development and to "obtain clinical proof of principle in humans". The current CORDIS record gives 31 May 2026 as the end date. A Patsnap entry last updated in May 2025 lists HB-086 as preclinical; that older entry cannot establish the current development stage.
Company file
- Legal entity
- Hoba Therapeutics ApS, CVR 38231170
- Founded
- November 2016 by Novo Holdings and Borean Innovation
- Headquarters
- Copenhagen, Denmark
- Chief executive
- Torsten M. Madsen
- Candidates
- HB-086 (recombinant human meteorin, nerve pain); HB-097 (hearing loss)
- Investors
- Indaco, Medical Incubator Japan, Novo Holdings, Eir Ventures, EIFO, EIC Fund
- EIC project
- Sense21, 1 Jun 2022 to 31 May 2026, closed
- Funding type (table)
- Grant first, equity decided later
Where Hoba Stands Today
Hoba is a lean, investor-backed drug developer. The financial year to March 2025 shows three employees, which should not be treated as a count of all contractors or collaborators. CORDIS identifies external manufacturing and toxicology providers. Its lead programme targets painful chemotherapy-induced peripheral neuropathy (CIPN), the nerve damage many cancer patients are left with after treatment. The pipeline tracker Patsnap Synapse, updated in May 2025, lists recombinant human meteorin as preclinical for trigeminal neuralgia, neuralgia and Huntington's disease, with no registered trial.
The money to get to the clinic arrived in December 2023. Novo Holdings announced a €23 million Series A first close led by Indaco Venture Partners and Medical Incubator Japan, with Novo Holdings, Eir Ventures, EIFO and the EIC Fund. The stated aim was to take HB-086 "through late pre-clinical development to the completion of Phase 1 clinical studies in patients" with CIPN. Searches for HB-086, Hoba and first-patient/Phase 1 announcements on 2 November 2026 did not establish a study start. The company pipeline and news pages timed out, limiting this check.
The Technology: A Protein Intended to Support Nerve Repair
Hoba's science rests on meteorin and cometin, a family of human proteins that act as neurotrophic factors: signals that help nerve cells and their supporting glial cells survive and repair. HB-086 is a manufactured version of meteorin. In animal models of neuropathic pain, according to the company, it gives fast and long-lasting relief and can even prevent the pain from developing, a potential disease-modifying effect that remains to be established clinically.
The EIC project added a telling detail. The CORDIS report notes that HB-086 stays in the blood for only four to five hours, yet its effect lasts far longer, a preclinical pharmacokinetic/pharmacodynamic observation consistent with the proposed mechanism, not proof of nerve repair or clinical efficacy. HB-097, the hearing-loss molecule, "preserves the sense of hearing in relevant models". These are preclinical findings; patient efficacy and safety require clinical evidence.
Madsen said the investor syndicate and financing would support the company's development objectives.
Torsten M. Madsen, chief executive, Hoba Therapeutics, Series A announcement, December 2023What the EIC Project Promised, and What CORDIS Shows
The EIC project
EU contribution: 70% of Sense21's €3.32M budget
Current CORDIS dates: June 2022-May 2026. Recorded budget allocation, distinct from proof of disbursement.
CORDIS project 190142580. Values in € millions.
Sense21 ran from 1 June 2022 to 31 May 2026 in the current CORDIS record. Its objective on CORDIS was plain: take HB-086 and HB-097 into clinical development and obtain clinical proof of principle in humans, first in healthy volunteers and then in patients. The CORDIS reporting page reviewed on 2 November 2026 displayed a first-period summary ending May 2023, last updated in July 2023. A later public summary was not located on that page; this does not establish whether reports were submitted privately.
- Scalable manufacturing of HB-086DeliveredFirst pilot batch in May 2023, 20% above projected yield; technology transferred to a contract manufacturer.
- Regulatory toxicology packageStartedStudy protocols completed and ethical approvals obtained by mid-2023; results not published.
- First-in-human studiesNot verifiedThe reviewed CORDIS summary and dated Patsnap record do not establish first dosing. Company pipeline/news access failed during the November 2026 check.
- Clinical proof of principleNot verifiedPatient results were not identified in the sources reviewed on 2 November 2026; absence of public data is not proof that no study occurred.
- Public final reportingNot locatedCORDIS shows only the first-year report, last updated July 2023.
What Has Happened Since the Award
The record
Reported manufacturing progress and unresolved clinical evidence
The current CORDIS project end date is May 2026. An older tracker entry does not establish current clinical status.
- Nov 2016Company foundedFounded by Novo Holdings and Borean Innovation, CVR 38231170
- Jun 2021EIC Accelerator cut-offSense21 submitted: HB-086 for nerve pain, HB-097 for hearing loss
- Jun 2022EIC project startsThree-year project to reach clinical proof of principle€2.33M grant
- May 2023First pilot batchHB-086 manufactured at 20% above projected yield; transferred to a contract manufacturer
- Dec 2023Series A first closeLed by Indaco and Medical Incubator Japan, with the EIC Fund€23M
- Mar 2025Financial year closesLoss of DKK 43.0M with three employees−DKK 43.0M
- Mar 2026Newer annual financial summaryeStatistik reports DKK 67.7M net loss and DKK 1.14M equity
- May 2026EIC project endsCurrent CORDIS end date; later clinical outcomes not established by the reviewed first-period summary
Danish company register data via Proff, CORDIS project 190142580, Novo Holdings and Patsnap Synapse. eStatistik annual-account summary, March 2026.
The beneficiary reports progress on manufacturing. Protein drugs live or die on manufacturing, and, according to its first CORDIS report, it scaled HB-086 production beyond its own projections within a year. It then raised a €23 million Series A from a syndicate that included a Japanese incubator and the EIC Fund. The reviewed sources do not establish first dosing; the dated and inaccessible sources limit conclusions about the present stage.
The Money
Hoba's accounts for the financial year ending March 2025, reported by Proff, show substantial reported losses; these totals alone do not establish external-development spending. Gross profit was minus DKK 38.3 million, the pre-tax loss DKK 48.5 million, and the net loss DKK 43.0 million after a tax credit. Equity at year end was DKK 26.1 million, about €3.5 million, against total assets of DKK 46.1 million.
The balance sheet
Reported balances and loss for the year to March 2025
Historical DKK million figures. Loss, assets and equity are different accounting measures, not a runway calculation. A March 2026 summary is discussed in the article.
Filed annual accounts of Hoba Therapeutics ApS via Proff.
Runway requires cash-flow information
Equity is not cash and a net loss is not cash burn. A runway assessment requires cash balances, committed financing and projected expenditure. A newer annual-account summary for March 2026 reports approximately DKK 67.7M net loss, DKK 1.14M equity and DKK 15.58M total assets. Those later balances do not by themselves establish insolvency or current financing needs.
Why Europe Should Care
A disease-modifying treatment for nerve damage caused by chemotherapy would matter to cancer patients after their treatment ends, and a non-opioid approach could offer an alternative to opioid therapies. Its own safety and dependence profile require clinical evaluation. The hearing-loss programme targets a second sensory disorder with few drug options. Both fit the EIC's 2021 remit of backing breakthrough health technologies that private investors alone would not yet fund.
Hoba is also a case of layered public backing: founded by Novo Holdings and Borean Innovation, supported with an EU grant and EU equity, and financed alongside Italian and Japanese investors. The public investors are in it from both Copenhagen and Brussels.
What the EIC funded
HB-086 and HB-097 taken into clinical development, with clinical proof of principle in humans under the project objective.
What the record shows
Manufacturing reportedly scaled, a €23M Series A raised and toxicology started, while the November 2026 review did not establish clinical results or locate a later summary on the CORDIS reporting page.
The Verdict
Preclinical progress, later evidence unresolved
Hoba reports pilot manufacturing and investor support for clinical development. The accessible CORDIS summary describes early preclinical progress, while the project now carries a May 2026 end date. The sources reviewed here do not establish the full later clinical outcome. That evidential gap should prompt further verification rather than a conclusion that clinical work never occurred or that grant obligations were breached.
Hoba Therapeutics has not been asked for comment for this article. It is based entirely on public records, company statements and EU project data, linked throughout.
Industry
HealthBiopharmaceuticals
- Focus
- Recombinant proteins
- Technologies
- Protein engineering
- Keywords
- Neuropathic pain
- Chemotherapy-induced neuropathy
- Hearing loss
- Neurotrophic factors